Lakefront Biotherapeutics NV 

Galapagos NV functions as an integrated biopharmaceutical enterprise, concentrating its efforts on identifying, developing, and marketing a diverse range of medications aimed at critical unaddressed medical conditions. The company's comprehensive pipeline includes several significant experimental therapies. Leading this portfolio is filgotinib, a JAK1 inhibitor that is currently progressing through various clinical trial phases for the management of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel Crohn's disease, fistulizing Crohn's disease, ankylosing spondylitis, psoriatic arthritis, and uveitis. Additionally, their developmental assets feature GLPG1972, which has successfully completed its Phase 2b trial for osteoarthritis. A series of "Toledo" compounds, namely GLPG3970, GLPG4399, and GLPG4876, are in development for inflammatory conditions. GLPG4716 and Ziritaxestat are also part of the pipeline, targeting idiopathic pulmonary fibrosis. Further pipeline advancements include GLPG2737, a cystic fibrosis transmembrane conductance regulator undergoing Phase 2 clinical trials for patients afflicted with autosomal dominant polycystic kidney disease. Another JAK1 inhibitor, GLPG0555, is in Phase 1b development for osteoarthritis. Galapagos NV has established collaborative agreements with major industry players such as Gilead Sciences, Inc., AbbVie S.à r.l., and Novartis Pharma AG. The company was established in 1999 and its headquarters are located in Mechelen, Belgium.